CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic ...
Phase 3
Charlotte, North Carolina, United States and 37 other locations
To assess the efficacy and safety of pirtobrutinib in participants with CLL/SLL who have progressed on first-line treatment with acalabrutinib.
Phase 2
Charlotte, North Carolina, United States and 12 other locations
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is...
Phase 1
Charlotte, North Carolina, United States and 18 other locations
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...
Phase 2
Charlotte, North Carolina, United States and 51 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Charlotte, North Carolina, United States and 216 other locations
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...
Phase 3
Charlotte, North Carolina, United States and 179 other locations
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...
Phase 3
Charlotte, North Carolina, United States and 86 other locations
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have...
Phase 3
Rock Hill, South Carolina, United States of America and 231 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Charlotte, North Carolina, United States and 216 other locations
Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common ...
Phase 1
Charlotte, North Carolina, United States and 13 other locations
Clinical trials
Research sites
Resources
Legal